Zymeworks (NASDAQ:ZYME) Stock Rating Lowered by Wall Street Zen

Key Points

• Zymeworks' stock rating has been downgraded by Wall Street Zen from a "strong-buy" to a "buy" in a recent research report.
• Despite the downgrade, the company has a consensus rating of "Buy" among analysts, with some firms issuing strong-buy ratings while others maintain sell recommendations.
• As of the last earnings report, Zymeworks reported a loss of ($1.14) EPS and generated revenue of $4.40 million, with a negative net margin of 59.96%.

Zymeworks (NASDAQ:ZYME - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "strong-buy" rating to a "buy" rating in a research report issued on Sunday.

A number of other analysts have also issued reports on the company. HC Wainwright raised Zymeworks from a "hold" rating to a "strong-buy" rating in a report on Tuesday, October 14th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Zymeworks in a report on Wednesday, October 8th. Finally, B. Riley raised Zymeworks to a "strong-buy" rating in a report on Thursday, October 9th. Two research analysts have rated the stock with a Strong Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy".

Zymeworks Stock Performance

Shares of NASDAQ ZYME opened at $18.40 on Friday. Zymeworks has a 12 month low of $9.03 and a 12 month high of $19.50. The stock has a market capitalization of $1.38 billion, a P/E ratio of -18.97 and a beta of 1.51. The company's fifty day moving average is $15.76.

Zymeworks (NASDAQ:ZYME - Get Free Report) last announced its earnings results on Tuesday, November 8th. The company reported ($1.14) EPS for the quarter. The company had revenue of $4.40 million for the quarter. Zymeworks had a negative net margin of 59.96% and a negative return on equity of 21.59%.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.